FDA approves additional recommended dosage for Keytruda

The FDA approved an additional recommended dosage of pembrolizumab, authorizing its use at 400 mg every 6 weeks.The new dosage option — available in addition to the previously approved dose of 200 mg every 3 weeks — applies to all adult indications for pembrolizumab (Keytruda, Merck).The anti-PD-1 therapy is approved for use as monotherapy and as part of combination therapy for multiple cancer types.“The important social distancing measures for COVID-19 have created a number of challenges for people with cancer, including keeping to planned treatment schedules,” RoyRead More

Share on facebook
Share on twitter
Share on linkedin